Belgium-based biotech Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a Phase I/II trial in Charcot-Marie-Tooth (CMT) disease.

Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. This novel non-hydroxamate, non ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. This novel non-hydroxamate, non-hydrazine ...

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing ...